

M11



The
Patent
Office

PCT/EP 99/06886
09/787327
INVESTOR IN PEOPLE

EP 99/6886

EPO - DG 1

13. 10. 1999

(86)

REC'D 28 OCT 1999

WIPO The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



D. Mahoney

Signed

Dated 9 September 1999.

THIS PAGE BLANK (USPTO)

s Act 1977
(16)

The
Patent
Office

21SEP98 E391394-1 D01030
D01/7700 25.00 - 9820420.9

1/77

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH1. Your F HKQ/SCH/PU35142. Patent **9820420.9** 18 SEP 1998
(The Patent office will fill in this part)3. Full name, address and postcode of the or of each applicant (underline all surnames)

GLAXO GROUP LIMITED
 GLAXO WELLCOME HOUSE
 BERKELEY AVENUE
 GREENFORD
 MIDDLESEX
 UB6 0NN

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its corporation

473 587003

4. Title of the invention **ANTIVIRAL COMBINATIONS**5. Name of your agent (if you know one)

HELEN K. QUILLIN
 (SEE CONTINUATION SHEET)

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

GLAXO WELLCOME PLC
 GLAXO WELLCOME HOUSE, BERKELEY AVENUE
 GREENFORD, MIDDLESEX
 UB6 0NN, GB

Patents ADP number (if you know it)

6470 579002

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of Filing (day / month / year)
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------	----------------------------------------------	-------------------------------------

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)
-------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------	-------------------------------------

8. Is a statement of inventorship and of right to grant a patent required in support of this request? (Answer yes if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body.	YES
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	1
Description	19
Claim(s)	3
Abstract	1
Drawing(s)	1 + 1



10. If you are also filing any of the following, state how many against each item

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patent Form 9/77*)

Request for substantive examination
(*Patent Form 10/77*)

Any other documents
(*please specify*)

11.

I/We request the grant of a patent on the basis of this application



Signature: Helen K. Quillin

18 September 1998

AGENT FOR THE APPLICANTS

12. Name and daytime telephone number of person to contact in the United Kingdom

Kim Allen

0181-966 5721

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

a) **Notes**

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form
If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Antiviral Combinations

5 The present invention relates to therapeutic combinations comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one (lamivudine) and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine, (PMEA or adefovir) and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine, [the oral
10 prodrug of PMEA, adefovir dipivoxil]. The present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus.

15 Hepatitis B is a viral disease transmitted orally or parentally by contaminated material such as blood or blood products, contaminated needles, sexually, and vertically from infected or carrier mothers to their off-spring. In those areas of the world where the disease is common, vertical transmission at an early age results
20 in a high proportion of infected individuals becoming chronic carriers of hepatitis B. An estimated 350 million people world-wide are chronically infected with hepatitis B and as many as 150 million may die from liver disease in the absence of intervention.

25 Currently, the only established approach to treatment of hepatitis B is repeated injections of interferon, which may be associated with unpleasant side effects, and produces a long lasting response in only one third or less of those treated. Interferon is an immune modulator designed to boost the disease fighting ability of the immune system.

30 Lamivudine has been reported to be effective against HBV in a two year study, showing that most patients showed substantially reduced levels of viral replication with 52% maintaining undetectable levels of virus thorough to the end of the second year.

Adefovir has been reported to posses anti-HBV activity in vitro, and the oral prodrug of adefovir, adefovir dipivoxil, has been shown to be active against HBV replication in vivo and is currently in phase II clinical studies with patients who have chronic hepatitis B viral infection.

5

There has been a report that there is lack of cross-resistance to PMEA for Human hepatitis B DNA polymerase which expresses lamivudine codons, X. Xiong et al. (Hepatology Vol 26, No. 4, Pt. 2, 1997, Abstract No. 1211).

10 The use of combinations of the invention may give rise to equivalent antiviral effect with reduced toxicity, or an increase in drug efficacy because synergy between compounds occurs. Lower overall drug doses will also possibly reduce the frequency of occurrence of drug resistant variants of HBV.

15 We have now found that lamivudine exhibits unexpected advantages when used in combination with adefovir. In particular the combinations shows a statistically significant synergistic anti-HBV effect. Early results have shown that the combination of lamivudine and adefovir dipivoxil also exhibits a synergistic anti-HBV-effect. It is a feature of this invention that the use of these drug 20 combinations will provide synergistic antiviral effects, more complete viral suppression, viral suppression over longer periods, limit the emergence of drug resistant HBV mutants and allow better management of drug related toxicities.

25 As will be appreciated by those skilled in the art, references herein to treatment extend to prophylaxis as well as to the treatment of established infections and symptoms.

Pharmaceutically acceptable salts of lamivudine, adefovir, or adefovir dipivoxil include those derived from pharmaceutically acceptable inorganic and organic acids. Examples of suitable acids include hydrochloric, hydrobromic, sulphuric, nitric, perchloric, fumaric, maleic, phosphoric, glycollic, lactic, salicylic, succinic, toluene- p-sulphonic, tartaric, acetic, citric, methanesulphonic, formic, benzoic, malonic, naphthalene-2-sulphonic and benzenesulphonic acids. Other acids such as oxalic acid, while not in themselves pharmaceutically acceptable may 35 be useful in the preparation of salts useful as intermediates in obtaining

compounds of the invention and their pharmaceutically acceptable acid addition salts.

Salts derived from appropriate bases include alkali metal (e.g. sodium), alkaline earth metal (e.g. magnesium), ammonium and NR_4^+ (where R is C_{1-4} alkyl) salts.

5 Preferred esters of lamivudine, adefovir or adefovir dipivoxil are independently selected from the following group: (1) carboxylic acid esters in which the non-
10 carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, methyl, n -propyl, t -butyl, or n -butyl), cycloalkyl, alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxyethyl), aryl (for example, phenyl or optionally substituted by, for example, halogen, C_{1-4} alkyl, or C_{1-4} alkoxy), or
15 amino; (2) sulphonate esters, such as alkyl- or aralkylsulphonyl (for example, methanesulphonyl); (3) amino acid esters (for example, L-valyl or L-isoleucyl); and (4) phosphonate esters. In such esters, unless otherwise specified, any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms. Any cycloalkyl moiety present in such esters advantageously contains from 3 to 6 carbon atoms. Any aryl moiety present in such esters advantageously comprises a phenyl group. Any reference to any of the above compounds also includes a reference to a physiologically acceptable salt thereof.

20 25 Particularly preferred esters are the mono-, di-, and triphosphate esters of lamivudine (which may be optionally blocked), or any other compound which upon administration to a human subject is capable of providing (directly or indirectly) said mono-, di-, or triphosphate ester.

30 Thus according to one aspect, the present invention provides a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-

[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.

5 *Preferably the second therapeutic agent is bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.*

10 *Combinations as described above may herein after be referred to as combinations according to the invention.*

15 *As used herein "pharmaceutically acceptable derivative" includes any pharmaceutically acceptable salt, ester or salt of such ester, of lamivudine, adefovir or adefovir dipivoxil or any other compound which, upon administration to the recipient, is capable of providing (directly or indirectly) such a compound or an antivirally active metabolite or residue thereof.*

20 *The present invention further provides combinations according to the invention for use in therapy, particularly in the treatment of an HBV infection including infections resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus.*

25 *According to another aspect, the present invention provides a method for the treatment of a mammal, including a human, suffering from an HBV infection comprising administration of a therapeutically effective amount of a combination according to the invention.*

30 *It will be appreciated that the compounds of the combination may be administered simultaneously, either in the same or different pharmaceutical composition, or sequentially. If there is sequential administration, the delay in administering the second active ingredient should not be such as to lose the benefit of a synergistic therapeutic effect of the combination of the active ingredients. It will also be understood that lamivudine, and adefovir dipivoxil, or the pharmaceutically acceptable derivatives thereof or adefovir or the pharmaceutically acceptable derivatives thereof, whether presented simultaneously or sequentially, may be administered individually or in any*

combination thereof. Lamivudine, and adefovir dipivoxil or adefovir are preferably administered simultaneously or sequentially in separate pharmaceutical formulations, most preferably simultaneously.

5 Preferably the combination according to the invention is administered as a single combined formulation.

The present invention also provides the use of lamivudine in the manufacture of a medicament for administration simultaneously or sequentially with adefovir or adefovir dipivoxil for the treatment of HBV infections. It will be appreciated that lamivudine, adefovir dipivoxil, or adefovir or any combination thereof (excluding adefovir and adefovir dipivoxil), may be used in the manufacture of the above medicament.

10 15 A further aspect of the invention is a combination according to the invention wherein the lamivudine and adefovir dipivoxil or adefovir are present in a synergistic ratio.

20 The synergistic effects of the combination of lamivudine and adefovir dipivoxil or adefovir or pharmaceutically acceptable derivatives thereof are seen over a ratio, for example, of 40:1 to 1:1 (by weight), preferably 25:1 to 15:1 (by weight).

25 Conveniently each compound will be employed in the combination in an amount at which it exhibits anti-HBV activity when used alone.

The amount of a combination of lamivudine, adefovir or adefovir dipivoxil required to be effective as an anti-HBV agent will, of course, vary and is ultimately at the discretion of the medical practitioner. The factors to be

30 considered include the route of administration and nature of the formulation, the animal's body weight, age and general condition and the nature and severity of the disease to be treated.

In general for lamivudine a suitable daily dose will be in the range of from about 35 0.1 to about 50 mg per kilogram body weight of the recipient per day, preferably

in the range of 0.5 to 20 mg per kilogram body weight per day, most preferably in the range of 0.5 to 2 mg per kilogram body weight per day.

5 The compound is conveniently administered at a level of about 100 mg per day.

For adefovir dipivoxil a suitable daily dose will be in the range of from about 0.01 to about 10 mg per kilogram body weight of the recipient per day, preferably in the range of 0.01 to 1 mg per kilogram body weight per day, most preferably in the range of 0.01 to 0.05 mg per kilogram body weight per day.

10 Conveniently adefovir dipivoxil is administered at a level of about 10 mg per day.

15 For adefovir, a suitable daily dose will be in the range of from about 0.01 to about 10 mg per kilogram body weight of the recipient per day, preferably in the range of 0.01 to 1 mg per kilogram body weight per day, most preferably in the range of 0.01 to 0.05 mg per kilogram body weight per day.

20 Conveniently adefovir is administered at a level of about 10 mg per day.

Unless otherwise indicated all weights of active ingredients are calculated in terms of the drug per se. In the case of a pharmaceutically acceptable derivatives of lamivudine, adefovir dipivoxil or adefovir, or a solvate of any

25 thereof the figures would be increased proportionately. The desired dose is preferably presented as two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing from 1 to 1500 mg, preferably from 5 to 1000 mg, most preferably from 5 to 500 mg of active

30 ingredient per unit dosage form. Alternatively, if the condition of the recipient so requires, the dose may be administered as a continuous infusion.

35 The components of the combination which may be referred to as active ingredients may be administered for therapy to an animal e.g. a mammal including a human in a conventional manner.

While it is possible for the active ingredients of the combination to be administered as the raw chemical it is preferable to present them as a pharmaceutical composition. Pharmaceutical compositions according to the 5 present invention comprise a combination according to the invention in association with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents. The carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formula and not deleterious to the recipient thereof. When the individual components of the 10 combination are administered separately they are generally each presented as a pharmaceutical composition. The references hereinafter to compositions refer unless otherwise stated to compositions containing either the combination or a component thereof.

15 A combination of lamivudine and adefovir dipivoxil or adefovir or pharmaceutically acceptable derivatives thereof may conveniently be presented as a pharmaceutical composition with one or more pharmaceutically acceptable carrier thereof in a unitary dosage form. A convenient unitary dosage formulation contains the active ingredients in amounts of from 1 mg to 2 g each, for 20 example, 2 mg to 200 mg such as 25 to 150 mg of lamivudine and 5 to 60 mg of adefovir or adefovir dipivoxil.

25 Pharmaceutical compositions may also be prescribed to the patient in "patient packs" containing the whole course of treatment in a single package, usually a blister pack. Patient packs have an advantage over traditional prescriptions, where a pharmacists divides a patients supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions. The inclusion of a package insert has been shown to improve patient compliance with the 30 physicians instructions.

35 It will be understood that the administration of the combination of the invention by means of a single patient pack, or patients packs of each composition, within a package insert diverting the patient to the correct use of the invention is a desirable additional feature of this invention.

According to a further aspect of the invention there is provided a patient pack comprising at least one active ingredient of the combination according to the invention and an information insert containing directions on the use of the combination of the invention.

According to another aspect the invention provides a double pack comprising in association for separate administration lamivudine and adefovir dipivoxil or adefovir or pharmaceutically acceptable derivatives thereof.

Compositions include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods represent a further feature of the present invention and include the step of bringing into association the active ingredients with the carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.

Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, caplets, cachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium

carboxymethyl cellulose) surface-active or dispersing agent. Moulded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredients therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.

10 Preferably the combinations according to the invention are administered orally.

Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier. Compositions for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

20 Topical administration may also be by means of a transdermal iontophoretic device.

25 Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

Pharmaceutical formulations suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories. Suitable 30 carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by admixture of the active combination with the softened or melted carrier(s) followed by chilling and shaping in moulds.

Formulations suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents; and

5 liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition

10 requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

15 Preferred unit dosage formulations are those containing a daily dose or daily subdose of the active ingredients, as herein before recited, or an appropriate fraction thereof.

20 It should be understood that in addition to the ingredients particularly mentioned above the formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavouring agents.

25 The compounds of the combination of the present invention may be obtained in a conventional manner.

Methods for the preparation of lamivudine are described in International Patent Applications Numbers. WO91/17159, and WO 95/29174 incorporated herein by

30 reference.

Methods for the preparation of adefovir are described in European Patent No. 206459, incorporated herein by reference.

Methods for the preparation of adefovir dipivoxil are described in European Patent 481214 incorporated herein by reference.

5 The following examples are intended for illustration only and are not intended to limit the scope of the invention in any way. "Active ingredient" denotes lamivudine, adefovir dipivoxil or adefovir or multiples thereof or a physiologically functional derivative of any of the aforementioned compounds.

10 Example 1: Tablet Formulation

The following formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.

15

Formulation A

	<u>mg/tablet</u>
Active Ingredient A	100
Active Ingredient B	30
Lactose B.P.	105
Povidone B.P.	7
Sodium Starch Glycollate	10
Magnesium Stearate	3
	255

Formulation B

	<u>mg/tablet</u>
Active Ingredient A	100
Active Ingredient B	30
Lactose B.P.	75
Avicel PH 101	30

12

Povidone B.P.	7
Sodium Starch Glycollate	10
Magnesium Stearate	3

	255

Formulation C

	<u>mg/tablet</u>
Active Ingredient A	100
Active Ingredient B	5
Lactose B.P.	100
Starch	25
Povidone	2
Magnesium Stearate	2

	234

5

The following formulations, D and E, are prepared by direct compression of the admixed ingredients. The lactose in formulation E is of the direct compression type (Dairy Crest - "Zeparox").

Formulation D

	<u>mg/tablet</u>
Active Ingredient A	100
Active Ingredient B	30
Pregelatinized Starch NF15	75

205

10

Formulation E

	<u>mg/tablet</u>
Active Ingredient A	100

Active Ingredient B	5
Lactose B.P.	70
Avicel	50
	225

Formulation F (Controlled Release Formulation)

The formulation is prepared by wet granulation of the ingredients with a solution of povidone followed by the addition of magnesium stearate and compression.

5

	<u>mg/tablet</u>
Active Ingredient A	100
Active Ingredient B	30
Hydroxypropylmethylcellulose (Methocel K4M Premium)	28
Lactose B.P.	13
Povidone B.P.	7
Magnesium Stearate	2
	180

Drug release takes place over a period of about 6-8 hours and is complete after 12 hours.

10 **Example 2: Capsule Formulations**

Formulation A

A capsule formulation is prepared by admixing the ingredients of formulation D

15 in Example 1 above and filling into a two-part hard gelatin capsule. Formulation B (infra) is prepared in a similar manner.

Formulation B

mg/capsule

Active Ingredient A	100
Active Ingredient B	5
Lactose B.P.	70
Sodium Starch Glycollate	10
Magnesium Stearate	1

186

Formulation C

	<u>mg/capsule</u>
Active Ingredient A	100
Active Ingredient B	30
Macrogel 4000 B.P.	170
<hr/>	
	300

5 Capsules of formulation C are prepared by melting the Macrogel 4000 B.P., dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule.

Formulation D

	<u>mg/capsule</u>
Active Ingredient A	100
Active Ingredient B	5
Lecithin	50
Arachis Oil	50
<hr/>	
	205

10 Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.

Formulation E (Controlled Release Capsule)

The following controlled release capsule formulation is prepared by extruding ingredients a, b, and c using an extruder, followed by spheronization of the extrudate and drying. The dried pellets are then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.

5

		<u>mg/capsule</u>
	(a) Active Ingredient A	100
	Active Ingredient B	30
	(b) Microcrystalline Cellulose	60
	(c) Lactose B.P.	60
	(d) Ethyl Cellulose	6
		<hr/>
		256

Example 3: Injectable Formulation

10

Formulation A

	<u>mg</u>
Active Ingredient A	100
Active Ingredient B	5
Hydrochloric Acid Solution 0.1 M or	
Sodium Hydroxide Solution 0.1 M q.s. to pH	4.0 to 7.0
Sterile water q.s. to	10 ml

The active ingredient is dissolved in most of the water (35°-40°C) and the pH

15

adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate. The batch is then made up to volume with the water and filtered through a sterile micropore filter into a sterile 10 ml amber glass vial (type 1) and sealed with sterile closures and overseals.

20

Formulation B

Active Ingredient A	125 mg
Sterile, Pyrogen-free, pH 7 Phosphate	
Buffer, q. s. to	25 ml

Example 4: Intramuscular injection

Active Ingredient A	100 mg
Active Ingredient B	30 mg
Benzyl Alcohol	0.067 g
Glycofurol 75	0.94 g
Water for injection q.s. to	3.00 ml

5

The active ingredient is dissolved in the glycofurol. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1).

10

Example 5: Syrup

Active Ingredient A	100 mg
Active Ingredient B	5 mg
Sorbitol Solution	0.6 g
Glycerol	0.85 g
Sodium Benzoate	0.0025 g
Flavour, Peach 17.42.3169	0.0125 ml
Purified Water q.s. to	5.00 ml

15

The active ingredient is dissolved in a mixture of the glycerol and most of the purified water. An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbital solution and finally the flavour. The volume is made up with purified water and mixed well.

Example 6: Suppository

	<u>mg/capsule suppository</u>
Active Ingredient A	100
Active Ingredient B	30
Hard Fat, B.P. (Witepsol H15 - Dynamit Nobel)	1770
	<hr/>
	1900

5 One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200µM sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining 10 Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250µm stainless steel screen and, with continuous stirring, is allowed to cool to 40°C. At a temperature of 38°C to 40°C, 2.02 g of the mixture is filled into suitable, 2 ml plastic moulds. The suppositories are allowed to cool to room temperature.

Example 7: Pessaries

	<u>mg/pessary</u>
Active Ingredient A	100
Active Ingredient B	5
Anhydride Dextrose	160
Potato Starch	150
Magnesium Stearate	3
	<hr/>
	418

15

The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture.

Biological Data

5 The human hepatoblastoma cell line (Hep-G2-2.2.15) which constitutively produces infectious HBV was seeded into 96 well microtiter plates at a density of 5×10^3 cells per well. These cells were treated with a combination of lamivudine and PMEA on triplicate plates. Culture media containing drugs was replenished every other day for 9 days, at which time supernatants were collected and analyzed for HBV content.

10 The lamivudine/PMEA combination was tested twice in triplicate in matrix fashion. Experiment 1 utilised a lamivudine range of 100 nM to 0.14 nM (3-fold dilutions in columns), and PMEA, 9-[(R)-2-(phosphonomethoxy)ethyl]adenine (adefovir), at concentrations of 1 μ M to 10 nM (3.16 fold dilutions in rows). Experiment 2 was performed with dilutions of Lamivudine ranging from 100nM to .045 nM (in 3-fold dilutions in columns), and a PMEA range of 5 μ M to 0.16 nM (3.16 fold dilutions in rows). Both drugs were diluted in a separate 96 well

15 microtiter plate, and subsequently transferred onto plates containing the cell monolayers. Cells are grown in 150 μ l RPMI 1640 supplemented with 2 mM L-Glutamine and 10% fetal bovine serum. Prior to transfer of drug, 120 μ l of media was removed from the cells, leaving 30 μ l on the monolayers to prevent drying. 90 μ l of fresh media without drug was added, followed by the addition of 30 μ l of 5X drug dilutions. Lamivudine and PMEA were each tested on their respective plates individually at the same concentrations. Data were normalised to values obtained with non-drug treated cells, and expressed as a percent of control for analysis.

20 The method used for detection of HBV has been previously described (Jansen RW, Johnson LC, Averett, DR. High-Capacity *in vitro* assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. *Antimicrob Agents Chem* 1993; 37 (3): 441-447.). Briefly, HBV detection was performed by "capturing" virus from supernatants on Anti-HBsAg

coated plates, washing, denaturing to release HBV DNA, performing PCR with biotinylated primers, streptavidin capture of biotinylated PCR products with concomitant probe hybridization, addition of substrate, and reading optical densities of the colorimetric reaction. Dilutions of a standardized HBV-containing

5 supernatant were included on every plate, and HBV DNA concentrations of test wells were calculated from this HBV standard curve. The useful range of detection is at least .045 to 45 fg of HBV DNA, where 30 copies of the genome can be reliably detected. Samples were tested in conjunction with both positive (.448 fg/ μ l plasmid DNA) and negative (RPMI medium supplemented with 2 mM 10 L-Glutamine and 10% Fetal calf serum) controls.

The average IC50 and standard error of the IC50s for the triplicate plates were calculated using SAS nonlinear regression to fit data to the Hill equation for each concentration response curve. When only a single determination of an IC50 for a particular dose combination could be made, the average of the standard errors from adjacent concentrations was used to estimate the standard error. Fractional inhibitory concentrations (FIC50) were calculated for each combination and plotted using the isobogram representation (Berenbaum, M.C. (1985) The Expected Effect of a Combination of Agents: the General Solution. *J. Theor. Biol.* 114, 413-431). To assess statistical significance of 20 synergy or antagonism, an unpaired t-test was used to compare each sum of paired FIC50 values with the theoretical value of 1. P values less than 0.05 were considered statistically significant. Comparison of P values between experiments must be interpreted with great care, as the experiments utilized different test concentration ranges (or ranges useable by the isobogram 25 method). In some cases not all concentrations tested could support calculation of an IC50, since response was inhibited to a greater extent than 50 percent of control for all doses.

Figure 1 shows a single isobogram, produced by combining the data from both experiments, showing a statistically significant synergism.

Claims

1. A combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.
2. A combination according to claim 1 wherein the ratio is in the range 25:1 to 15:1 by weight of active ingredients.
3. A combination according to claim 1 or 2 wherein the second therapeutic agent is bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.
4. A combination according to any one of claims 1 to 3 for use in medicine.
5. A pharmaceutical formulation comprising a combination according to any one of claims 1 to 3 in association with one or more pharmaceutically acceptable carriers therefor.
6. A formulation according to claim 5 in unit dosage form.
7. A formulation according to any one of claims 5 to 6 suitable for oral administration.
8. A formulation according to any one of claims 5 to 7 comprising between 25 to 150 mg of lamivudine and 5 to 60 mg adefovir dipivoxil.

9. A formulation according to claim 8 comprising 100 mg of lamivudine and 10 mg adefovir dipivoxil.

10. A method for the treatment of a mammal, including a human, with an HBV infection comprising administration of a therapeutically effective amount of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof.

11. A method as claimed in claim 10 wherein the combination is as claimed in any of claims 1 to 3.

12. A method according to claim 10 or claim 11 wherein the combination is administered simultaneously.

13. A method according to claim 10 or claim 11 wherein the combination is administered sequentially.

14. A method according to claim 10 or claim 11 wherein the combination is administered as a single combined formulation.

15. A method as claimed in any one of claims 10 to 14 for the treatment of an HBV infection resistant to nucleoside and/or non-nucleoside inhibitors of the replication of the hepatitis B virus

16. Use of (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-

30 pyrimidin-2-one in the manufacture of a medicament for administration either simultaneously or sequentially with bis(pivaloyloxymethyl)(9-[(2-(phosphonomethoxy)ethyl]adenine, for the treatment of an HBV infection.

17. Use of bis(pivaloyloxymethyl)(9-[(2-(phosphonomethoxy)ethyl]adenine in the manufacture of a medicament for administration either simultaneously or

sequentially with (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one for the treatment of an HBV infection.

5 18. Use of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine 10 or a pharmaceutically acceptable derivative thereof for the treatment of an HBV infection.

15 19. Use of a combination as claimed in any one of claims 1 to 3 for the treatment of an HBV infection.

20 20. Use of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from either (9-[(R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof, or bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine 25 or a pharmaceutically acceptable derivative thereof for the treatment of an HBV infection resistant to nucleoside and/or nonnucleoside inhibitor.

25 21. Use of a combination as claimed in any one of claims 1 to 3 for the treatment of an HBV infection resistant to nucleoside and/or nonnucleoside inhibitor of the replication of the hepatitis B virus.

30 22. A patient pack comprising of at least one active ingredient selected from (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one, and bis(pivaloyloxymethyl)(9-[2-(phosphonomethoxy)ethyl]adenine and an information insert containing directions on the use of both active ingredients together in combination.

Abstract

The present invention relates to therapeutic combinations comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one (lamivudine) and 5 a second therapeutic agent selected from (9-[(R)-2-(phosphonomethoxy)ethyl]adenine, (PMEA or adefovir) and bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine, (the oral prodrug of PMEA, adefovir dipivoxil) which have anti-hepatitis B virus (HBV) activity. The present invention is also concerned with pharmaceutical 10 compositions containing said combinations and their use in the treatment of HBV infections including infections with HBV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.





Figure 1.



THIS PAGE BLANK (USPTO)